Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$618.46 USD
-5.75 (-0.92%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $618.47 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$618.46 USD
-5.75 (-0.92%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $618.47 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Fresenius Medical (FMS) Stock Gains 5.6% on Q3 Earnings Beat
by Zacks Equity Research
Fresenius Medical's (FMS) third-quarter earnings benefit from stable segmental performance.
Change Healthcare (CHNG) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
Change Healthcare's (CHNG) fiscal second-quarter results benefit from solid performance in the Network Solutions segment.
Cardinal Health (CAH) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cardinal Health's (CAH) fiscal first-quarter results reflect strong segmental performance.
AmerisourceBergen (ABC) Q4 Earnings & Revenues Top Estimates
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal fourth-quarter results benefit from segmental growth.
Surmodics (SRDX) Reports Q4 Loss, Revenues Beat Estimates
by Zacks Equity Research
Surmodics (SRDX) registered revenue decline in each of its core units in the fourth quarter.
Hologic (HOLX) Q4 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Hologic (HOLX) exhibited robust segmental growth in fourth-quarter fiscal 2020 driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.
Thermo Fisher (TMO) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Thermo Fisher (TMO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Pacific Biosciences (PACB) Loses 4.1% Post Reporting Q3 Loss
by Zacks Equity Research
Pacific Biosciences (PACB) saw revenue decline in both its operating segments in the third quarter.
Avanos Medical (AVNS) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avanos Medical (AVNS) continued to gain from core Chronic Care segment in the third quarter.
Intersect ENT (XENT) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Intersect ENT's (XENT) PROPEL implants gain momentum and recapture procedure volume in Q3 following the drop in elective sinus procedures.
McKesson (MCK) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
McKesson's (MCK) fiscal second-quarter 2021 results benefit from strong segmental performance.
Bruker's (BRKR) Q3 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Bruker's (BRKR) third-quarter 2020 results reflect dismal performances by two of the reporting segments and geographies due to coronavirus-led business disruptions.
Chemed's (CHE) Shares Up on Q3 Earnings and Revenue Beat
by Zacks Equity Research
Chemed (CHE) reports solid revenue growth across key subsidiaries in third-quarter results.
Accuray (ARAY) Climbs 11.5% as Q1 Earnings Beat Estimates
by Zacks Equity Research
Accuray (ARAY) registered growth in Service revenues in Q1.
STERIS' (STE) Earnings & Revenues Surpass Estimates in Q2
by Zacks Equity Research
STERIS' (STE) second-quarter fiscal 2021 results reflect strong performance by the Life Sciences and the Applied Sterilization Technologies segments despite the coronavirus-led economic crisis.
Teleflex (TFX) Q3 Earnings & Revenues Beat, Decline Y/Y
by Zacks Equity Research
Teleflex (TFX) witnesses significant sequential improvement in segmental performance on gradual recovery of the economy.
Syneos Health (SYNH) Q3 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Syneos Health (SYNH) registers sales decline in both its business segments due to slower recovery in reimbursable out-of-pocket expenses across both segments.
Illumina (ILMN) Q3 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Illumina (ILMN) exhibits dismal segmental performance in the third quarter of 2020 due to pandemic-led business disruptions.
NuVasive (NUVA) Q3 Earnings Beat, Gross Margin Declines
by Zacks Equity Research
NuVasive (NUVA) registers strong international performance in Q3 along with several spinal hardware product lines growing at high single digits or more.
ResMed (RMD) Q1 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
ResMed's (RMD) overall increase in Q1 revenues is driven by robust performance of its mask and device product portfolios on increased demand for ventilators and ventilator masks.
Exact Sciences (EXAS) Loses 5.6% Despite Beating Q3 Earnings
by Zacks Equity Research
Exact Sciences' (EXAS) legacy screening business sees a decline in revenues in Q3 earnings.
Henry Schein (HSIC) Q3 Earnings Top Estimates, Margins Dip
by Zacks Equity Research
Henry Schein (HSIC) sees robust segmental performance in Q3 boosted by strong rebound in sales and solid demand for PPE and COVID-19-related products.
OPKO Health (OPK) Loses 16.2% Despite In-Line Q3 Earnings
by Zacks Equity Research
OPKO Health's (OPK) third-quarter results benefit from increase in RAYALDEE prescriptions.
Allscripts (MDRX) Declines 1.9% Despite Q3 Earnings Beat
by Zacks Equity Research
Allscripts (MDRX) witnessed decline in core Client Services and Software delivery unit revenues during the third quarter.
Amedisys (AMED) Beats Q3 Earnings Estimates, Ups 2020 View
by Zacks Equity Research
An impressive Q3 performance by Amedisys' (AMED) Home health and hospice amid the pandemic-led business disruptions buoys optimism.